LynxDX: Building the next generation of prostate cancer diagnostics

LynxDx is working to commercialize a prostate cancer urine diagnostic assay that is able to confidently prevent many unnecessary prostate biopsies. The test, called the MyProstateScore (MPS), is performed in a regulatory-compliant commercial laboratory.

To assist in the global response to the COVID-19 pandemic, LynxDx has worked aggressively to repurpose our clinical laboratory infrastructure to offer diagnostic COVID-19 testing, and is now Michigan’s largest provider of COVID-19 testing.

Integrate Now

Contact Redox to learn how your organization can integrate any of the healthcare products listed here today.